IDH1 and acute myeloid leukemia: This suggests that IDH1/2mt AML can develop resistance mechanisms that confer D-2-HG independence or that D-2-HG production is not homogeneously stopped in all malignant cells within IDH1/2mt AML with residual D-2-HG production still occurring in the CSC compartment.